We are currently treating patients in the State of Arizona and Indiana
Semaglutide
Injected once a week and can help people lose an average of 15-20% of their body weight over a 12-month period.
Reduced appetite
Slower digestion
Increased insulin production
Reduced calorie absorption
GLP-1 receptor agonists, which work by stimulating the release of insulin and reducing the production of glucagon in the body. This helps to lower blood sugar levels and can also lead to weight loss.
Tirzepatide
Tirzepatide is injected once a week and can help people lose an average of 15-20% of their body weight over a 12-month period. It has been shown to outperform semaglutide in comparative studies. However, it is more expensive.
Reduced appetite
Slower digestion
Increased insulin production
Reduced calorie absorption
Tirzepatide is a dual GLP-1/GIP receptor agonist, while semaglutide is a GLP-1 receptor agonist. GIP is another hormone that is released after eating and helps to regulate appetite and digestion. By targeting both GLP-1 and GIP receptors, tirzepatide may be more effective at reducing appetite and weight than semaglutide.
IV Infusions
Mobile IV Therapy
Add-On/Boosters
Testing
NAD+ Treatment
Peptides
Physician Consult / Urgent Care
